# Solid lipid nanoparticles as carriers for Ulva rigida peptide extract with demonstrated anti-β-amyloid and antioxidant properties

**Authors:** Tânia G. Tavares, Iva Carvalho, Maria João Ramalho, Stéphanie Andrade, Maria Carmo Pereira, Joana A. Loureiro

PMC · DOI: 10.3389/fnagi.2026.1778124 · Frontiers in Aging Neuroscience · 2026-03-13

## TL;DR

Researchers found that peptides from a green algae called Ulva rigida can reduce harmful protein buildup linked to Alzheimer's and improve their delivery using nanoparticles.

## Contribution

The study introduces a novel nanoformulation using solid lipid nanoparticles to enhance the delivery of Ulva rigida peptides with anti-β-amyloid and antioxidant properties.

## Key findings

- Peptides from Ulva rigida reduced Aβ1–42 aggregation by about 60% in vitro.
- The nanoformulation had a size of 158 ± 14 nm and 54.1% encapsulation efficiency.
- The peptides showed antioxidant capacity of 2.51 ± 0.18 μmolTrolox equivalent/mg hydrolyzed protein.

## Abstract

Alzheimer’s disease (AD) remains one of the greatest challenges in neurodegenerative research, largely due to the toxic aggregation of the β-amyloid (Aβ) peptide and the difficulty of delivering therapeutic compounds across the blood-brain barrier (BBB).

This work explored Ulva rigida (U. rigida), a green macroalga rich in bioactive peptides, as a natural source of anti-amyloidogenic and antioxidant agents.

First, the peptides extraction process was optimized by design of experiments (DoE). Peptides extracted and hydrolyzed under optimized conditions showed antioxidant capacity (2.51 ± 0.18 μmolTrolox equivalent/ mghydrolyzed protein), and the fraction of peptides with a molecular weight lower than 3 kDa was able to reduce the aggregation of Aβ1–42 peptide in vitro by around 60%. To overcome the issue of limited bioavailability, we encapsulated these peptides in solid lipid nanoparticles (SLNs). The developed nanoformulation displayed a size of 158 ± 14 nm, narrow polydispersity, and near-neutral zeta potential (−4.7 ± 0.6 mV), with an encapsulation efficiency (EE) of 54.1 ± 0.1% and suitable stability under simulated gastrointestinal and storage conditions.

By combining biological activity with a delivery platform, this study highlights the potential of Ulva rigida as a source of bioactive peptides with the potential to delay the progression of AD.

## Linked entities

- **Proteins:** FDI57_gp42 (endonuclease)
- **Diseases:** Alzheimer's disease (MONDO:0004975)
- **Species:** Ulva rigida (taxon 75689)

## Full-text entities

- **Genes:** APP (amyloid beta precursor protein) [NCBI Gene 351] {aka AAA, ABETA, ABPP, AD1, APPI, CTFgamma}
- **Diseases:** AD (MESH:D000544)
- **Chemicals:** Ulva rigida peptide (-), lipid (MESH:D008055)
- **Species:** Ulva rigida (species) [taxon 75689]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13021872/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13021872/full.md

## References

55 references — full list in the complete paper: https://tomesphere.com/paper/PMC13021872/full.md

---
Source: https://tomesphere.com/paper/PMC13021872